This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Multiple New Studies Discuss Clinical Benefits Of Given Imaging's PillCam(R) COLON At United European Gastroenterology Week

- Ten abstracts including more than 1,200 patients to be presented on PillCam COLON - - Topics range from confirming the diagnostic yield of PillCam COLON and validating feasibility of PillCam COLON in a general practice setting -  

BERLIN, Oct. 14, 2013 (GLOBE NEWSWIRE) -- Given Imaging Ltd, (Nasdaq:GIVN), a world leader in gastrointestinal medical devices and pioneer of capsule endoscopy, today announced that ten abstracts highlighting the clinical utility of PillCam COLON were presented during United European Gastroenterology Week (UEG Week) taking place October 12-16, 2013 at the Internationales Congress Centrum Berlin where Given Imaging is exhibiting at Hall 15.1, Booth #7.

"The growing body of data supporting both the clinical accuracy for PillCam COLON and patient preference for a non-invasive, radiation-free colorectal exam strengthen our efforts to expand access to PillCam COLON in Europe and markets across the globe," said Homi Shamir, president and CEO, Given Imaging.

Highlights of the ten studies presented at UEG Week include:
  • Patients prefer PillCam COLON because of concern about pain and embarrassment related to colonoscopy.
  • PillCam COLON shows significantly higher diagnostic yield compared to CTC in polyps 6 mm or larger.
  • Use of PillCam COLON following incomplete colonoscopy reveals new lesions in 60% of patients resulting in therapy modifications for 45% of these patients.  
  • Head-to-head, retrospective comparison of PillCam COLON versus colonoscopy finds PillCam COLON generated 90% sensitivity and 96% specificity on a per-lesion basis for detecting flat lesions shown to have a higher risk of being cancerous.

"As utilization of PillCam COLON increases, we are generating useful information about its use in a range of settings and for different indications including polyp detection rates," said Jean-Christophe Saurin, M.D., Ph.D., French Society of Digestive Endoscopy. "These quantifiable outcomes underscore that PillCam COLON is an interesting colonic screening option for patients who cannot or prefer not to have a traditional colonoscopy, but studies on acceptance in these patients are warranted."
  • " French Multicenter Experience of Colon Capsule Endoscopy in Real Practice: Primary Results of the Colon Capsule Endoscopy Observatory 'ONECC'" (poster #1337) was conducted by Dr. Saurin and colleagues to analyze survey results from a 161-user, 116-center French database of PillCam COLON procedures. Researchers evaluated the feasibility of using PillCam COLON in a general practice setting and the indications for which PillCam COLON was being used. Survey results from 585 PillCam procedures showed that PillCam COLON detected polyps in 253 patients, of which, significant polyps were discovered in 125 patients, or 28% of all the PillCam COLON procedures. Researchers also discovered that PillCam was used equally among three indications: patients with previous incomplete colonoscopy, patients contraindicated for colonoscopy and patients who refused colonoscopy. Of these indications, PillCam COLON detected significant polyps in 20.4% of patients with previous incomplete colonoscopy, 23.1% of patient contraindicated for colonoscopy and 14.5% of patients who refused colonoscopy. Based on the broad indications used for PillCam COLON and the significant polyp detection rate, researchers confirmed the practical application of PillCam COLON in a general practice setting.
  • " Patients Perception of Colonoscopy: Astonishing Reasons for Colon Capsule Endoscopy Preference" (poster #791) validated patient preference for a non-invasive colorectal exam. Researchers from the Department of Gastroenterology and Hepatology at the Institute for Clinical and Experimental Medicine in Prague, Czech Republic led by Marek Benes, M.D. conducted a 100 patient survey analysis to find that 42% of patients reported they will never undergo a screening colonoscopy even though 45% of this subgroup had a positive family history of colorectal cancer. The top reason for preference for PillCam COLON over colonoscopy was due to concerns about privacy and embarrassment experienced with colonoscopy, with 38% of patients reporting this as their top concern. Concern of pain was the second most common reason to prefer PillCam COLON over colonoscopy, with 35% of patients reporting this as a concern.
  • " Flat Colorectal Lesions At Pillcam Colon Capsule Endoscopy" (oral presentation #432) was a head-to-head, retrospective comparison of PillCam COLON versus colonoscopy to evaluate the ability of PillCam COLON to diagnose flat colonic lesions. Led by Cristiano Spada, M.D., Catholic University, Rome, Italy, researchers collected data from patients who underwent PillCam COLON followed by a traditional colonoscopy. Physicians were able to identify 27 conventional polyps with colonoscopy and 25 conventional polyps with PillCam COLON. In one patient, PillCam COLON visualized an 11 mm flat lesion that was not confirmed by colonoscopy. PillCam COLON generated 90% sensitivity and 96% specificity on a per-lesion basis. Based on these findings, researchers concluded that PillCam COLON has high accuracy for detecting flat lesions. 

The utilization of PillCam COLON following incomplete colonoscopy was highlighted in UEG Week abstracts including:
  • " Colon Capsule Endoscopy Versus CT-Colonography in the Evaluation of Patients with Incomplete Traditional Colonoscopy: A Prospective Comparative Trial" (oral presentation #431) presented by Cristiano Spada, M.D., and colleagues from the Catholic University in Rome, Italy. Patients in the study underwent both CT-colonography (CTC) and PillCam COLON with the goal of identifying polyps and masses that were at least six millimeters and located in segments of the colon that could not be examined in the previous incomplete colonoscopy. Both PillCam COLON and CTC successfully completed the colonic exam in 98% of patients due to 2% of patients refusing CTC due to air insufflation. Of the 98 patients included in the analysis, PillCam COLON identified polyps at least six millimeters in size in 19 patients, while CTC identified only seven patients. Resulting sensitivity and specificity for PillCam COLON was 100% and 91% respectively and 35% and 92% respectively for CTC. Researchers concluded that both exam modalities were effective in completing a colonic exam, however PillCam COLON had a significantly higher diagnostic yield compared to CTC in identifying polyps six millimeters or larger. 
  • " Utility of Colon Capsule Endoscopy After an Incomplete Colonoscopy - Multicenter Spanish Study" (poster #793) led by Oscar Nogales, M.D., Hospital General Universitario Gregorio Marañón, Department of Gastroenterology, Madrid, Spain analyzed the use of PillCam COLON 98 patients with previous incomplete colonoscopies. Overall, PillCam COLON was able to identify new lesions in in 60% of patients. Within this group, therapy modifications resulted for 45% of the patients. Polyps were the most frequent finding with 41% of patients having a polyp identified by PillCam COLON. Additional findings by PillCam COLON included diverticulae, neoplasia and solitary colonic ulcers. Based on these results, researchers concluded that Pillam COLON is a useful diagnostic tool to identify a significant number of lesions in unexplored regions of the colon following incomplete colonoscopy and, as a result, may produce favorable therapeutic changes for these patients.

About PillCam COLON

The PillCam COLON video capsule is equipped with two miniature color video cameras (one on each end), a battery and an LED light source; it measures 11 mm X 31 mm. PillCam COLON is designed to be ingested by the patient and transmit up to 35 frames per second for approximately 10 hours to a recording device worn by the patient. Data are transferred from the device to a computer that uses RAPID software to compile the video data and enable the physician to review and report the results of the PillCam study.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.15 0.54%
FB $117.93 -0.54%
GOOG $695.24 -0.43%
TSLA $233.65 -3.40%
YHOO $36.06 -1.30%


Chart of I:DJI
DOW 17,701.19 -189.97 -1.06%
S&P 500 2,058.43 -23.00 -1.10%
NASDAQ 4,759.1050 -58.4890 -1.21%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs